Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 15/20 | 0.68 |
| ▸ | CDK1 | P06493 | 14/20 | 0.68 |
| ▸ | CDK2 | P24941 | 13/20 | 0.68 |
| ▸ | CCND1 | P24385 | 13/20 | 0.68 |
| ▸ | CDK9 | P50750 | 11/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.68 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.68 |
| ▸ | CDK8 | P49336 | 4/20 | 0.68 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.68 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.58 |
| ▸ | CCND3 | P30281 | 4/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.58 |
| ▸ | CCNC | P24863 | 1/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.49 |
| ▸ | GSK3A | P49840 | 4/20 | 0.49 |
| ▸ | CDK7 | P50613 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30688746 | 1.00 | CDK4 (0.68) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL31632765 | 0.99 | CDK4 (0.67) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL30688749 | 0.99 | CDK4 (0.67) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL4015958 | 0.99 | CDK4 (0.67) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL23682929 | 0.90 | CDK4 (0.71) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL666139 | 0.86 | CDK4 (0.65) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL3108179 | 0.86 | CDK2 (0.51) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL665647 | 0.85 | CDK4 (0.66) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL3119657 | 0.85 | CDK4 (0.51) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL6120236 | 0.85 | CDK2 (0.49) | CDK4CDK1CDK2CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | disclosed |
| US-20250195467-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2025-06-19 | — | — | US | disclosed |
| US-12076309-B2 | Compounds for the treatment of cancers associated with human papillomavirus | Piramal Enterprises Limited (IN) | 2024-09-03 | — | — | US | disclosed |
| US-20240165076-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2024-05-23 | — | — | US | disclosed |
| CN-117731786-A | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-111053768-B | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11839591-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2023-12-12 | — | — | US | disclosed |
| US-20220023263-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2022-01-27 | — | — | US | disclosed |
| US-20210393589-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2021-12-23 | — | — | US | disclosed |
| US-11160789-B2 | Compounds for the treatment of cancers associated with human papillomavirus | Piramal Enterprises Limited (IN) | 2021-11-02 | — | — | US | disclosed |
| US-20130237582-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | Piramal Enterprises Limited (IN) | 2013-09-12 | — | — | US | disclosed |
| WO-2013105056-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | Piramal Enterprises Limited (IN) | 2013-07-18 | — | — | WO | disclosed |
| CN-103037860-A | Pyrrolidine Substituted Flavones For The Treatment Of Inflammatory Disorders | PIRAMAL LIFE SCIENCES LTD | 2013-04-10 | — | — | CN | disclosed |
| EP-2538941-A1 | PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012176163-A2 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2012-12-27 | — | — | WO | disclosed |
| US-20120316216-A1 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-13 | — | — | US | disclosed |
| WO-2011104584-A1 | PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-09-01 | — | — | WO | disclosed |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Piramal Enterprises Limited (IN) | 2010-07-15 | — | — | US | disclosed |
| EP-2046738-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | Piramal Life Sciences Limited (IN) | 2009-04-15 | — | — | EP | disclosed |
| WO-2007148158-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023263-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK2 53/4885 |
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CDK2 10/4885 |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CDK2, CDK9, CDK1 | CDK4 5/4885CDK1 3/4885CDK2 1/4885 |
| US-20130237582-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | CCNI, CDK1, CDKL1 | CDK4 7/4885CDK1 2/4885CDK2 24/4885 |
| US-20120316216-A1 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, SYVN1, PAH | CDK4 1833/4885CDK1 842/4885CDK2 1402/4885 |
| US-11839591-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CDK2 10/4885 |
| US-12076309-B2 | Compounds for the treatment of cancers associated with human papillomavirus | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK2 53/4885 |
| US-20210393589-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CDK2 10/4885 |
| US-20250195467-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK2 53/4885 |
| US-20240165076-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CDK1, CDK6 | CDK4 15/4885CDK1 2/4885CDK2 70/4885 |
| US-11160789-B2 | Compounds for the treatment of cancers associated with human papillomavirus | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.